- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04900701
The Impact of Energy Intake and Short-term Disuse on Muscle Protein Synthesis Rates and Skeletal Muscle Mass in Middle-aged Adults. (PIE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background Age related muscle tissue loss, which is associated with a number of negative health outcomes is partially caused by blunted muscle protein synthesis rates (MPS) in response to food ingestion, which is exacerbated by muscle disuse. Concomitantly, consuming an energy balanced diet appears to become more challenging with advancing age, due to a reduction in appetite. Of concern is that the impact of energy intake on muscle protein metabolism during ageing is poorly characterised.
Objective To determine daily MPS and muscle morphology in response to differing energy intakes, in free-living conditions and during immobilisation.
Methods Healthy middle-aged volunteers will consume a hypocaloric, energy-balanced, or hypercaloric diet (providing 1.4 g.kg.day protein) over a three-day free-living period, and a three day period of single leg immobilisation. Deuterium oxide and MRI scans will be used to measure daily MPS and muscle size, respectively.
Value The study will determine the effect of energy intake per se on daily muscle protein synthesis rates and muscle size, in free-living and immobilised conditions. This will inform how energy provision modulates tissue loss with ageing, and how this interacts with the catabolic stress of muscle disuse.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Devon
-
Exeter, Devon, United Kingdom, EX1 2LU
- University of Exeter, Sports & Health Sciences, College of Life & Environmental Sciences
-
Exeter, Devon, United Kingdom, EX1 2LU
- Sport & Health Sciences University of Exeter
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Age 35-65 Healthy Non-smoker Recreationally active
Exclusion Criteria:
Any diagnosed metabolic impairment (e.g. type 1 or 2 Diabetes) Any diagnosed cardiovascular disease or hypertension Elevated blood pressure at the time of screening. (An average systolic blood pressure reading of ≥150mmHg over two or more measurements and an average diastolic blood pressure of ≥90mmHg over two or more measurements.) Chronic use of diabetic medication. A personal or family history of epilepsy, seizures or schizophrenia. Allergic to mycoprotein / Quorn, penicillin, or cow's milk. Any musculoskeletal injury that may impair their use of crutches. Any diagnosed severe digestive illness. Any diagnosed severe autoimmune disease. Any diagnosed cancer. Any metal fragments in the eyes, a pacemaker, or metal implants in the body that preclude MRI scanning.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Hypocaloric
Participants placed in energy restriction.
|
Varying conditions of energy intake, thereby manipulating whether participants are in a state of energy restriction, balance, or surplus.
|
|
Experimental: Energy Balance
Participants placed in energy balance.
|
Varying conditions of energy intake, thereby manipulating whether participants are in a state of energy restriction, balance, or surplus.
|
|
Experimental: Hypercaloric
Participants placed in energy surplus.
|
Varying conditions of energy intake, thereby manipulating whether participants are in a state of energy restriction, balance, or surplus.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Muscle protein synthesis (MPS)
Time Frame: 6 days (3 days free-living, 3 days immobilised)
|
Daily muscle protein synthesis rates, expressed as fractional synthetic rate (FSR) (%/day)
|
6 days (3 days free-living, 3 days immobilised)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Muscle morphology.
Time Frame: 3 day immobilisation phase.
|
Changes in muscle size, measured via MRI scanning, during immobilisation.
|
3 day immobilisation phase.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Nervous System Diseases
- Neuromuscular Manifestations
- Nutrition Disorders
- Pathological Conditions, Anatomical
- Atrophy
- Deficiency Diseases
- Malnutrition
- Protein Deficiency
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Signs and Symptoms
- Muscular Atrophy
- Protein-Energy Malnutrition
Other Study ID Numbers
- 201209-B-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aging
-
Florida Institute for Human and Machine CognitionNot yet recruitingAging | Healthy Aging | Aging WellUnited States
-
Tuba MadenCompletedAging | Aging Problems | Aging Disorder
-
University of CopenhagenRecruitingAging | Healthy Aging | Aging FrailtyDenmark
-
Radboud University Medical CenterTerminated
-
Northwestern UniversityPotocsnak Human Longevity LabRecruitingAging | Aging Well | Aging, Biological | Aging, HealthyUnited States
-
Centre Hospitalier Universitaire de NiceNot yet recruitingAging | Aging, HealthyFrance
-
University of Santiago de CompostelaEuropean Regional Development Fund; Center for Industrial Technological Development...Completed
-
TruDiagnosticBlushield USANot yet recruitingAging | Aging Well
-
Arizona State UniversityActive, not recruiting
-
San Diego State UniversityCompleted
Clinical Trials on Energy status
-
Clinical Nutrition Research Centre, SingaporeCompleted
-
Guilin Medical University, Chinathe Affiliated hospital of Guilin medical university, ChinaRecruitingPsychological Distress | Unresectable Hepatocellular Carcinoma | Cancer, Treatment-Related | HCC - Hepatocellular Carcinoma | Immune Checkpoint Inhibitors (ICIs)China
-
University of Colorado, DenverUniversity of Alabama at Birmingham; Brown UniversityCompleted
-
Princess Al-Johara Al-Ibrahim Cancer Research CenterCompletedRenal StonesSaudi Arabia
-
University of FloridaCompletedCancerUnited States
-
Radicle ScienceCompletedFatigueUnited States
-
Radicle ScienceCompletedFatigue | EnergyUnited States
-
Washington University School of MedicineCompletedCardiovascular DiseasesUnited States
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States